Alexandria P. Cogdill

发表

B cells and tertiary lymphoid structures promote immunotherapy response

Jeffrey E. Lee, N. Hacohen, Keren Yizhak, 2020, Nature.

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.

Alexandria P. Cogdill, C. June, Xiaojun Liu, 2015, Cancer research.

Hallmarks of response to immune checkpoint blockade

J. Wargo, Alexandria P. Cogdill, M. Andrews, 2017, British Journal of Cancer.

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

E. Le Chatelier, N. Pons, N. Ajami, 2018, Science.

Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

Na Li, Andreas Loew, Gabriela Plesa, 2015, Science Translational Medicine.

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Mari Mino-Kenudson, Keith T Flaherty, Erin M. Coffee, 2012, Cancer discovery.

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Dana Pe’er, Yang Zhao, D. Pe’er, 2017, Cell.

COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation

Marc Vidal, Reinhard Dummer, William C. Hahn, 2010, Nature.

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

J. Byrd, A. Johnson, Alexandria P. Cogdill, 2016, Blood.

regression and targets normal tissues expressing cognate antigen Gene therapy with human and mouse T-cell receptors mediates cancer

S. Rosenberg, Alexandria P. Cogdill, R. Morgan, 2009 .

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

M. Ross, J. McQuade, B. Helmink, 2022, Nature.

Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?

J. Wargo, Alexandria P. Cogdill, A. Reuben, 2016, Clinical Cancer Research.

P854 Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets

Daniel K. Wells, V. Thorsson, Y. Najjar, 2020, Journal of Immunotherapy for Cancer.

Abstract LB-350: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition by vemurafenib

Erin M. Coffee, K. Flaherty, M. Mino‐Kenudson, 2012 .

Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.

J. Wargo, Alexandria P. Cogdill, S. Parangi, 2013, Surgery.

Androgen receptor activity promotes resistance to BRAF-targeted melanoma therapy

Jeffrey E. Lee, M. Ross, J. McQuade, 2020 .

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

Daniel K. Wells, C. Horak, B. Vincent, 2022, Cancer immunology research.

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

Jared C Malke, Julie M Simon, Christine B. Peterson, 2021, Science.

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

D. Pe’er, Jacob H. Levine, J. Wargo, 2019, Proceedings of the National Academy of Sciences.

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.

Alexandria P. Cogdill, C. June, M. Feldman, 2016, Immunity.

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

R. Sullivan, K. Flaherty, Dennie T. Frederick, 2013, Clinical Cancer Research.

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

K. Flaherty, J. Wargo, D. Fisher, 2010, Cancer research.

The human tumor microbiome is composed of tumor type–specific intracellular bacteria

Noam Shental, Eran Segal, Iris Barshack, 2020, Science.

Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas

Zev A. Binder, Alexandria P. Cogdill, D. O’Rourke, 2018, Molecular therapy oncolytics.

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

S. Rosenberg, Alexandria P. Cogdill, R. Morgan, 2009, Blood.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Tyler J. Reich, F. Bushman, S. Carty, 2018, Nature.

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma

Hannah C. Beird, Jeffrey E. Lee, L. Chin, 2017, npj Genomic Medicine.

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.

P. A. Futreal, M. Ross, J. McQuade, 2022, Journal of Clinical Oncology.

B cells and tertiary lymphoid structures promote immunotherapy response

Jeffrey E. Lee, N. Hacohen, Keren Yizhak, 2020, Nature.

The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy.

J. Wargo, V. Gopalakrishnan, Alexandria P. Cogdill, 2018, Trends in immunology.

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

N. Ajami, J. Petrosino, P. Opolon, 2020, Nature Medicine.

Interaction between Targeted Therapy and Immunotherapy

J. Wargo, Alexandria P. Cogdill, M. Andrews, 2018 .

Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Erin M. Coffee, K. Flaherty, M. Mino‐Kenudson, 2012 .

Abstract 958: Treatment with a selective inhibitor of BRAFV600E increases melanocyte antigen expression and CD8 T cell infiltrate in tumors of patients with metastatic melanoma

H. Ott, K. Flaherty, J. Wargo, 2011 .

The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies

J. Wargo, Alexandria P. Cogdill, E. Keung, 2018, Annals of Surgical Oncology.

Targeting the MAGE A3 antigen in pancreatic cancer.

Dennie T. Frederick, J. Wargo, Alexandria P. Cogdill, 2012, Surgery.

Abstract 5545: Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration

Xuegong Zhang, N. Ajami, J. Wargo, 2022, Cancer Research.

Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors

J. McQuade, B. Helmink, J. Wargo, 2019, Tumor Biology.

75 Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer

Daniel K. Wells, Dante S. Bortone, V. Thorsson, 2020 .